Viswanadhan Krishnan 4

What Happened

• Viswanadhan Krishnan, Chief Strategy and Operations at Agios Pharmaceuticals (AGIO), had 3,000 performance stock units (PSUs) converted and a corresponding grant of 3,000 restricted stock units (RSUs) reported on Form 4 for the June 18, 2026 transaction. Both entries show a $0.00 per-share price and $0 total value. This reflects a milestone-driven award/conversion (not an open-market buy or sale); the underlying shares related to the satisfied research milestone will vest on December 31, 2027, subject to Krishnan’s continued service.

Key Details

• Transaction date: June 18, 2026 (Form 4 filed June 23, 2026)
• Reported entries: M (exercise/conversion of derivative) — 3,000 units disposed @ $0.00; A (award/grant) — 3,000 units acquired @ $0.00
• Economic effect: no cash paid or received; conversion of contingent PSUs into RSUs
• Vesting: PSUs were originally granted March 5, 2025; the research milestone was certified June 18, 2026; related RSUs vest 12/31/2027 subject to continued service (see footnotes)
• Shares owned after transaction: not specified in the provided filing
• Timeliness: Form 4 was filed June 23 for a June 18 transaction — appears to be filed after the 2-business-day deadline for Form 4s (may be an administrative delay)

Context

• These entries reflect milestone-based equity compensation: PSUs (contingent rights to shares) were recognized as having met a research milestone and converted into RSUs (contingent rights to shares that vest later). There was no immediate issuance of free-trading shares or market sale, so this is not an indication of buying/selling activity by the insider.